Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I. Leboulleux S, et al. Among authors: betrian s. Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046. Clin Cancer Res. 2023. PMID: 37074727 Free article. Clinical Trial.
Management of patients with advanced epithelial ovarian cancer: a European survey.
Jochum F, Angeles MA, Balaya V, Drouin L, Nikolova T, Mathevet P, Lécuru F, Azais H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Guyon F, Akladios C, Hsu A, Bendifallah S, Deluche E, Guani B. Jochum F, et al. Among authors: betrian s. Arch Gynecol Obstet. 2023 Aug;308(2):535-549. doi: 10.1007/s00404-023-06948-3. Epub 2023 Feb 3. Arch Gynecol Obstet. 2023. PMID: 36737552
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study.
Martinez A, Lecuru F, Bizzarri N, Chargari C, Ducassou A, Fagotti A, Fanfani F, Scambia G, Cibula D, Díaz-Feijoo B, Gil Moreno A, Angeles MA, Muallem MZ, Kohler C, Luyckx M, Kridelka F, Rychlik A, Gerestein KG, Heinzelmann V, Ramirez PT, Frumovitz M, Ferron G, Betrian S, Filleron T, Fotopoulou C, Querleu D; PAROLA Study group. Martinez A, et al. Among authors: betrian s. Int J Gynecol Cancer. 2023 Feb 6;33(2):293-298. doi: 10.1136/ijgc-2022-004223. Int J Gynecol Cancer. 2023. PMID: 36717163 Clinical Trial.
[Application in France of the 2021 European recommendations on endometrial cancer].
Deluche E, Marti C, Jochum F, Bendifallah S, Azaïs H, Deidier J, Cockenpot V, Menoux I, Kissel M, Balaya V, Betrian S, Mathevet P, Chargari C, Gouy S, Genestie C, Uzan C, Devouassoux-Shisheboran M, Guyon F, Akladios C, Body N, Guani B; groupe SFOG et SFOG campus. Deluche E, et al. Among authors: betrian s. Bull Cancer. 2023 Jan;110(1):55-68. doi: 10.1016/j.bulcan.2022.11.003. Epub 2022 Nov 30. Bull Cancer. 2023. PMID: 36462971 Review. French.
Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.
Angeles MA, Spagnolo E, Cabarrou B, Pérez-Benavente A, Gil Moreno A, Guyon F, Rychlik A, Migliorelli F, Bataillon G, Navarro AS, Betrian S, Ferron G, Hernández A, Martinez A. Angeles MA, et al. Among authors: betrian s. Int J Gynecol Cancer. 2023 Jan 3;33(1):50-56. doi: 10.1136/ijgc-2022-003985. Int J Gynecol Cancer. 2023. PMID: 36446410
Management of Endometrial Cancer: French Society of Onco-Gynecology's Evaluation through a Delphi Survey.
Marti C, Deluche E, Jochum F, Bendifallah S, Azais H, Deidier J, Cockenpot V, Menoux I, Balaya V, Betrian S, Chargari C, Gouy S, Genestie C, Feki A, Uzan C, Guyon F, Devouassoux-Shisheboran M, Body N, Akladios C, Mathevet P, Guani B, On Behalf Of The Sfog And The Sfog Campus. Marti C, et al. Among authors: betrian s. J Clin Med. 2022 Nov 15;11(22):6765. doi: 10.3390/jcm11226765. J Clin Med. 2022. PMID: 36431242 Free PMC article.
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer.
Betrian S, Angeles MA, Gil Moreno A, Cabarrou B, Deslandres M, Ferron G, Mery E, Floquet A, Guyon F, Pérez-Benavente A, Spagnolo E, Rychlik A, Gladieff L, Hernández Gutiérrez A, Martinez A. Betrian S, et al. Int J Gynecol Cancer. 2022 Jul 20:ijgc-2021-003313. doi: 10.1136/ijgc-2021-003313. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35858711
31 results